Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 116

1.

Effectiveness of inpatient withdrawal and residential rehabilitation interventions for alcohol use disorder: A national observational, cohort study in England.

Eastwood B, Peacock A, Millar T, Jones A, Knight J, Horgan P, Lowden T, Willey P, Marsden J.

J Subst Abuse Treat. 2018 May;88:1-8. doi: 10.1016/j.jsat.2018.02.001. Epub 2018 Feb 7.

PMID:
29606222
2.

Effectiveness of community psychosocial and pharmacological treatments for alcohol use disorder: A national observational cohort study in England.

Peacock A, Eastwood B, Jones A, Millar T, Horgan P, Knight J, Randhawa K, White M, Marsden J.

Drug Alcohol Depend. 2018 Mar 13;186:60-67. doi: 10.1016/j.drugalcdep.2018.01.019. [Epub ahead of print]

PMID:
29550623
3.

Memory-Focused Cognitive Therapy for Cocaine Use Disorder: Theory, Procedures and Preliminary Evidence From an External Pilot Randomised Controlled Trial.

Marsden J, Goetz C, Meynen T, Mitcheson L, Stillwell G, Eastwood B, Strang J, Grey N.

EBioMedicine. 2018 Mar;29:177-189. doi: 10.1016/j.ebiom.2018.01.039. Epub 2018 Feb 2.

4.

Minimum Significant Ratio – A Statistic to Assess Assay Variability.

Haas JV, Eastwood BJ, Iversen PW, Devanarayan V, Weidner JR.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Hass JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2013 Nov 1 [updated 2017 Nov 20].

5.

Assay Operations for SAR Support.

Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Iversen PW, Kahl SD, Moore RA, Sawyer BD, Weidner J.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Hass JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2017 Nov 20].

6.

Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders.

Bruns RF, Mitchell SN, Wafford KA, Harper AJ, Shanks EA, Carter G, O'Neill MJ, Murray TK, Eastwood BJ, Schaus JM, Beck JP, Hao J, Witkin JM, Li X, Chernet E, Katner JS, Wang H, Ryder JW, Masquelin ME, Thompson LK, Love PL, Maren DL, Falcone JF, Menezes MM, Zhang L, Yang CR, Svensson KA.

Neuropharmacology. 2018 Jan;128:351-365. doi: 10.1016/j.neuropharm.2017.10.032. Epub 2017 Oct 26.

7.

Data Standardization for Results Management.

Campbell RM, Dymshitz J, Eastwood BJ, Emkey R, Greenen DP, Heerding JM, Johnson D, Large TH, Littlejohn T, Montrose C, Nutter SE, Sawyer BD, Sigmund SK, Smith M, Weidner JR, Zink RW.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Hass JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2017 Oct 20].

8.

Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy.

Blackmore T, Meftah S, Murray TK, Craig PJ, Blockeel A, Phillips K, Eastwood B, O'Neill MJ, Marston H, Ahmed Z, Gilmour G, Gastambide F.

Alzheimers Res Ther. 2017 Sep 20;9(1):77. doi: 10.1186/s13195-017-0306-2.

9.

Young People's Use of E-Cigarettes across the United Kingdom: Findings from Five Surveys 2015-2017.

Bauld L, MacKintosh AM, Eastwood B, Ford A, Moore G, Dockrell M, Arnott D, Cheeseman H, McNeill A.

Int J Environ Res Public Health. 2017 Aug 29;14(9). pii: E973. doi: 10.3390/ijerph14090973.

10.

Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors.

Witkin JM, Li J, Gilmour G, Mitchell SN, Carter G, Gleason SD, Seidel WF, Eastwood BJ, McCarthy A, Porter WJ, Reel J, Gardinier KM, Kato AS, Wafford KA.

Neuropharmacology. 2017 Nov;126:257-270. doi: 10.1016/j.neuropharm.2017.07.028. Epub 2017 Jul 28.

PMID:
28757050
11.

Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England.

Eastwood B, Strang J, Marsden J.

Drug Alcohol Depend. 2017 Jul 1;176:139-147. doi: 10.1016/j.drugalcdep.2017.03.013. Epub 2017 May 16.

PMID:
28535456
12.

Electronic cigarette use in young people in Great Britain 2015-2016.

Eastwood B, East K, Brose LS, Dockrell MJ, Arnott D, Cheeseman H, McNeill A.

Public Health. 2017 Aug;149:45-48. doi: 10.1016/j.puhe.2017.03.019. Epub 2017 May 19. No abstract available.

PMID:
28531448
13.

Investigating the neuroimmunogenic architecture of schizophrenia.

Birnbaum R, Jaffe AE, Chen Q, Shin JH; BrainSeq Consortium, Kleinman JE, Hyde TM, Weinberger DR.

Mol Psychiatry. 2017 May 9. doi: 10.1038/mp.2017.89. [Epub ahead of print]

PMID:
28485405
14.

Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England.

Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, Lowden T, Maddalena N, Metcalfe C, Shaw J, Hickman M.

Addiction. 2017 Aug;112(8):1408-1418. doi: 10.1111/add.13779. Epub 2017 Mar 1.

PMID:
28160345
15.

Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of Depression.

Witkin JM, Mitchell SN, Wafford KA, Carter G, Gilmour G, Li J, Eastwood BJ, Overshiner C, Li X, Rorick-Kehn L, Rasmussen K, Anderson WH, Nikolayev A, Tolstikov VV, Kuo MS, Catlow JT, Li R, Smith SC, Mitch CH, Ornstein PL, Swanson S, Monn JA.

J Pharmacol Exp Ther. 2017 Apr;361(1):68-86. doi: 10.1124/jpet.116.238121. Epub 2017 Jan 30.

16.

Modelling maintenance of wakefulness in rats: comparing potential non-invasive sleep-restriction methods and their effects on sleep and attentional performance.

Mccarthy A, Loomis S, Eastwood B, Wafford KA, Winsky-Sommerer R, Gilmour G.

J Sleep Res. 2017 Apr;26(2):179-187. doi: 10.1111/jsr.12464. Epub 2016 Oct 14.

17.

Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery.

Collier DA, Eastwood BJ, Malki K, Mokrab Y.

Ann N Y Acad Sci. 2016 Feb;1366(1):61-75. doi: 10.1111/nyas.13066. Review.

PMID:
27111133
18.

Is treatment for alcohol use disorder associated with reductions in criminal offending? A national data linkage cohort study in England.

Willey H, Eastwood B, Gee IL, Marsden J.

Drug Alcohol Depend. 2016 Apr 1;161:67-76. doi: 10.1016/j.drugalcdep.2016.01.020. Epub 2016 Jan 29.

PMID:
26861884
19.

BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders.

BrainSeq: A Human Brain Genomics Consortium. Electronic address: drweinberger@libd.org; BrainSeq: A Human Brain Genomics Consortium.

Neuron. 2015 Dec 16;88(6):1078-1083. doi: 10.1016/j.neuron.2015.10.047. Review.

20.

A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats.

Velez de Mendizabal N, Jackson K, Eastwood B, Swanson S, Bender DM, Lowe S, Bies RR.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):721-33. doi: 10.1007/s10928-015-9448-7. Epub 2015 Sep 22.

PMID:
26395999

Supplemental Content

Loading ...
Support Center